Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Kyverna Therapeutics, Inc. ( (KYTX) ) is now available.
On May 4, 2026, Kyverna Therapeutics appointed veteran biopharmaceutical executive Nadia Dac as Chief Commercial Officer, underscoring its shift toward becoming a commercial-stage cell therapy company. Kyverna develops miv-cel, a CD19-targeting CAR T-cell therapy for autoimmune diseases, with a strategic focus on neuroimmunology indications such as stiff person syndrome and generalized myasthenia gravis.
Dac brings more than three decades of U.S. and global commercial leadership, including launch experience in neurology and rare diseases at Omeros, Alder Biopharmaceuticals, AbbVie, Auxilium, Novartis, Biogen, Pfizer, Johnson & Johnson and Eli Lilly. Her appointment, accompanied by a multi-year stock option grant, is intended to strengthen Kyverna’s commercial capabilities as it prepares for potential product launches and scales its organization for long-term growth in competitive autoimmune and rare disease markets.
The most recent analyst rating on (KYTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Neutral.
The score is held back primarily by weak financial performance—no recent revenue, widening losses, and accelerating cash burn—despite a low-debt balance sheet. Offsetting factors include strong positive clinical-data corporate updates and moderately constructive technical momentum, while valuation is constrained by negative earnings and no indicated dividend support.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its lead candidate, miv-cel (mivocabtagene autoleucel, KYV-101), is an autologous CD19-targeting CAR T-cell therapy being advanced as a potentially first-in-class neuroimmunology franchise across multiple B-cell-driven autoimmune conditions.
The company has completed a registrational trial in stiff person syndrome and is running a registrational trial in generalized myasthenia gravis, while additional KYSA and investigator-initiated trials in diseases such as multiple sclerosis and rheumatoid arthritis are informing future indications. Kyverna is also building a next-generation pipeline of CAR T-cell therapies aimed at improving patient access and treatment experience.
Average Trading Volume: 833,947
Technical Sentiment Signal: Strong Buy
Current Market Cap: $536.9M
Learn more about KYTX stock on TipRanks’ Stock Analysis page.